Found: 286
Select item for more details and to access through your institution.
670 - Tapinarof cream 1% once daily is efficacious for the treatment of atopic dermatitis in patients with skin of color down to 2 years of age in two pivotal phase 3 trials.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.044
- By:
- Publication type:
- Article
626 - Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.010
- By:
- Publication type:
- Article
652 - Tralokinumab real-world use in adults with atopic dermatitis: baseline characteristics of the first 100 patients recruited to the TRACE study in the United States.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.031
- By:
- Publication type:
- Article
683 - Risk of major adverse cardiovascular events in patients with moderate-to-severe atopic dermatitis: a United States population-based study.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.057
- By:
- Publication type:
- Article
703 - Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with moderate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.077
- By:
- Publication type:
- Article
699 - Prevalence and incidence of atopic dermatitis in patients with alopecia areata in the United States: a population-based study.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.073
- By:
- Publication type:
- Article
667 - Maintenance of efficacy and safety with nemolizumab at week 48: results from two global phase 3 pivotal studies (ARCADIA-1 and ARCADIA-2) in patients with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.041
- By:
- Publication type:
- Article
732 - EASI 90 response sustained up to 38 weeks after lebrikizumab withdrawal despite negligible serum concentrations.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.105
- By:
- Publication type:
- Article
671 - Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.045
- By:
- Publication type:
- Article
680 - Efficacy of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis by age of onset: analysis of two phase 3 clinical trials.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.054
- By:
- Publication type:
- Article
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2235, doi. 10.1007/s13555-024-01224-x
- By:
- Publication type:
- Article
Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Trends in the Adoption of Outpatient Joint Arthroplasties and Patient Risk: A Retrospective Analysis of 2019 to 2021 Medicare Claims Data.
- Published in:
- Journal of the American Academy of Orthopaedic Surgeons, 2024, v. 32, n. 15, p. e741, doi. 10.5435/JAAOS-D-23-00572
- By:
- Publication type:
- Article
Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO‐1 and PSO‐2).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 8, p. 1543, doi. 10.1111/jdv.19925
- By:
- Publication type:
- Article
Depression screening for psoriasis in the United States: A population‐based study.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 8, p. e698, doi. 10.1111/jdv.19849
- By:
- Publication type:
- Article
Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 7, p. 1839, doi. 10.1007/s13555-024-01190-4
- By:
- Publication type:
- Article
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 7, p. 1849, doi. 10.1007/s13555-024-01183-3
- By:
- Publication type:
- Article
Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 7, p. 1891, doi. 10.1007/s13555-024-01201-4
- By:
- Publication type:
- Article
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 7, p. 1929, doi. 10.1007/s13555-024-01199-9
- By:
- Publication type:
- Article
Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 6, p. 1615, doi. 10.1007/s13555-024-01188-y
- By:
- Publication type:
- Article
Shared decision-making in psoriasis care: Evaluation of how patients' perception of clinicians' delivery of care changes by age and sex.
- Published in:
- PLoS ONE, 2024, v. 19, n. 5, p. 1, doi. 10.1371/journal.pone.0303058
- By:
- Publication type:
- Article
Effect of abrocitinib on skin biomarkers in patients with moderate‐to‐severe atopic dermatitis.
- Published in:
- Allergy, 2024, v. 79, n. 5, p. 1258, doi. 10.1111/all.15969
- By:
- Publication type:
- Article
Brodalumab: 5-Year US Pharmacovigilance Report.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 5, p. 1349, doi. 10.1007/s13555-024-01162-8
- By:
- Publication type:
- Article
Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis: A Systematic Review.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 5, p. 550, doi. 10.1001/jamadermatol.2023.5439
- By:
- Publication type:
- Article
Efficacy of long- term risankizumab treatment for moderate- to- severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 5, p. 864, doi. 10.1111/jdv.19748
- By:
- Publication type:
- Article
An OX-Tra'Ordinary Tale: The Role of OX40 and OX40L in Atopic Dermatitis.
- Published in:
- Cells (2073-4409), 2024, v. 13, n. 7, p. 587, doi. 10.3390/cells13070587
- By:
- Publication type:
- Article
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 4, p. 933, doi. 10.1007/s13555-024-01136-w
- By:
- Publication type:
- Article
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 4, p. 1007, doi. 10.1007/s13555-024-01147-7
- By:
- Publication type:
- Article
Conjunctivitis does not increase with longer duration of lebrikizumab exposure in patients with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii5, doi. 10.1093/bjd/ljad498.007
- By:
- Publication type:
- Article
Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii18, doi. 10.1093/bjd/ljad498.022
- By:
- Publication type:
- Article
Comparative efficacy of targeted systemic therapies with topical corticosteroids for moderate-to-severe atopic dermatitis: an updated network meta-analysis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii19, doi. 10.1093/bjd/ljad498.023
- By:
- Publication type:
- Article
Efficacy of upadacitinib and dupilumab on achieving stringent and composite skin and itch outcomes: an indirect comparison of adults with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii26, doi. 10.1093/bjd/ljad498.029
- By:
- Publication type:
- Article
A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii53, doi. 10.1093/bjd/ljad498.055
- By:
- Publication type:
- Article
Tralokinumab real-world use in adults with atopic dermatitis: baseline characteristics of the first 100 patients recruited to the TRACE study in the United States.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii54, doi. 10.1093/bjd/ljad498.056
- By:
- Publication type:
- Article
Evaluating Treatment Choice in Patients with Moderate to Severe Psoriasis in the United States: Results from a US Patient Survey.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 2, p. 421, doi. 10.1007/s13555-023-01089-6
- By:
- Publication type:
- Article
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 2, p. 204, doi. 10.1001/jamadermatol.2023.5058
- By:
- Publication type:
- Article
Correction to: Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2024, v. 90, n. 1, p. 1, doi. 10.25259/IJDVL_15_2023
- By:
- Publication type:
- Article
Evaluation of DermSat-7 for Assessing Treatment Satisfaction in Patients with Acne.
- Published in:
- JAMA Dermatology, 2024, v. 160, n. 1, p. 88, doi. 10.1001/jamadermatol.2023.4481
- By:
- Publication type:
- Article
Comorbidity Burden in Psoriasis Patients With Skin of Color.
- Published in:
- Journal of Psoriasis & Psoriatic Arthritis, 2024, v. 9, n. 1, p. 16, doi. 10.1177/24755303231198482
- By:
- Publication type:
- Article
Assessing the Quality, Comprehensiveness, and Readability of Online Patient Health Resources About Psoriasis in Skin of Color.
- Published in:
- Journal of Clinical & Aesthetic Dermatology, 2023, v. 16, n. 12, p. 52
- By:
- Publication type:
- Article
Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 Annual Meeting.
- Published in:
- Journal of Rheumatology, 2023, v. 50, p. 1, doi. 10.3899/jrheum.2023-0496
- By:
- Publication type:
- Article
Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics ?
- Published in:
- Journal of Rheumatology, 2023, v. 50, p. 11, doi. 10.3899/jrheum.2023-0511
- By:
- Publication type:
- Article
GRAPPA 2021 Pilot Grant Award Reports.
- Published in:
- Journal of Rheumatology, 2023, v. 50, p. 36, doi. 10.3899/jrheum.2023-0524
- By:
- Publication type:
- Article
GRAPPA 2022 Trainee Symposium: A Summary of Oral and Poster Presentations.
- Published in:
- Journal of Rheumatology, 2023, v. 50, p. 41, doi. 10.3899/jrheum.2023-0526
- By:
- Publication type:
- Article
Report of the Skin Research Workgroups From the IDEOM Breakout at the GRAPPA 2022 Annual Meeting.
- Published in:
- Journal of Rheumatology, 2023, v. 50, p. 47, doi. 10.3899/jrheum.2023-0528
- By:
- Publication type:
- Article
Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 6, p. 913, doi. 10.1007/s40257-023-00809-0
- By:
- Publication type:
- Article
Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 6, p. 939, doi. 10.1007/s40257-023-00806-3
- By:
- Publication type:
- Article
Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2589, doi. 10.1007/s13555-023-00977-1
- By:
- Publication type:
- Article
Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice